Financial report outlook | With a 16x PE ratio hanging by a thread, Novartis AG Sponsored ADR (NVS.US) has three heavy-hitting new drug data releases in the second half of the year that will serve as a "litmus test" for valuation.

Notice that as investors in Novartis AG Sponsored ADR (NVS.US) focus on the quarterly earnings announced on Tuesday, they are also looking ahead to the three major drug trial results expected to be announced in the second half of this year, which are seen as key to proving the premium valuation of this Swiss pharmaceutical company. Wall Street expects Novartis AG Sponsored ADR's revenue for the second quarter of 2026 to be $14.12 billion, a 4.86% decrease from the previous year; and adjusted earnings per share to be $2.14, compared to $2.42 in the same period last year. Analysts say that these experimental drugs - pelacarsen for cardiovascular disease, remibrutinib for multiple sclerosis, and a drug for treating genetic diseases del-desiran - could determine the growth prospects of the company for the next decade, as the looming patent expiry clouds continue to put pharmaceutical companies' research pipelines under increasing scrutiny. Ketan Patel, fund manager at Whitefriars, a London-based investor in Novartis AG Sponsored ADR, said, "The market can be brutal when it comes to research... even the slightest shortcomings in clinical trials can be heavily penalized, and impressive results only provide temporary relief." Earlier this month, the stock of British company Astrazeneca PLC Sponsored ADR fell after a drug trial for a neurological disease related to heart failure failed. Vasant Narasimhan, CEO of Novartis AG Sponsored ADR for the past eight years, expects the company to achieve growth during what he calls its largest patent expiry period in history. James Gordon, an analyst at Barclays PLC Sponsored ADR, said, "The body language displayed by management regarding these (trials) results will be a major focus of attention." Analysts estimate that these three drugs collectively represent over $10 billion in peak annual sales potential, which will offset the expected losses resulting from the expiration of patents for the bestselling drugs Cosentyx for psoriasis and arthritis, and Kisqali for breast cancer therapy in the US and Europe around the turn of the decade. Sales of heart disease drug Entresto are already facing competition from generics, with sales expected to decline by $4 billion this year. Trial results are key in valuation Some analysts warn that much of the potential upside from trial results has already been reflected in Novartis AG Sponsored ADR's industry-leading valuation, with a forward P/E ratio of around 16 times. The company's stock has risen 11% so far this year and about a quarter in the past 12 months. Michael Leuchten, analyst at Jefferies Financial Group Inc., said, "At a 16 times P/E ratio, you really need these growth levers to deliver." "It's more about the momentum in the second half of the year, where you may want to consider some slightly riskier pipeline data that lies ahead." High analyst James Quigley says Novartis AG Sponsored ADR needs at least two out of the three trials to have good results. "If two of them fail, the 16 times P/E ratio will look very, very fragile," he said. Management confidence Investors will closely watch management's confidence, the timing of result announcements, and the framing of benefits around "clinical significance", which often determines if the drug's efficacy is significant enough to be accepted by doctors, patients, and payers. UBS Group AG analysts expect pelacarsen to achieve statistical significance of around 12% relative risk reduction, but clinical doctors may want to see 15% or higher before deeming the results clinically meaningful. Pelacarsen is the first of the three trials to be unveiled, with its HORIZON study testing whether lowering lipoprotein (a) (Lp(a)) can reduce the risk of heart attack or stroke. Sven Borho, managing partner at investment firm OrbiMed, said, "Lp(a) is particularly interesting because there are currently no similar drugs on the market." The company manages the investment portfolio of Worldwide Healthcare Trust, which recently invested in Novartis AG Sponsored ADR. Borho said that if Novartis AG Sponsored ADR's drug is the first to market, it could become a major sales driver. "This will be a huge market because once you start using it, you have to keep taking it for the rest of your life."